PTIXW VS HTGM Stock Comparison

Performance

PTIXW
10/100

PTIXW returned -30.00% in the last 12 months. Based on SPY's performance of -13.78%, its performance is below average giving it a score of 10 of 100.

HTGM
10/100

HTGM returned -93.22% in the last 12 months. Based on SPY's performance of 2.57%, its performance is below average giving it a score of 10 of 100.

Profit

PTIXW
10/100

Out of the last 20 quarters, PTIXW has had 0 profitable quarters and has increased their profits year over year on 0 of them.

HTGM
10/100

Out of the last 20 quarters, HTGM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

PTIXW
67/100

PTIXW has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

HTGM
37/100

HTGM has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.

Analyst Price Targets

PTIXW

"Analyst Price Targets" not found for PTIXW

HTGM
88/100

2 analysts offer 12-month price targets for HTGM. Together, they have an average target of 0.17, the most optimistic target put HTGM at 0.17 within 12-months and the most pessimistic has HTGM at 0.17. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

Technicals

PTIXW

"Technicals" not found for PTIXW

HTGM
14/100

HTGM receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

PTIXW

"Earnings" not found for PTIXW

HTGM
10/100

HTGM has missed earnings 5 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

Protagenic Therapeutics, Inc. Warrant Summary

Nasdaq / PTIXW

Healthcare

Biotechnology

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

HTG Molecular Diagnostics, Inc. Common Stock Summary

Nasdaq / HTGM

Healthcare

Diagnostics & Research

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Power up your portfolio